49.52
-0.32 (-0.64%)
| Previous Close | 49.84 |
| Open | 49.89 |
| Volume | 1,099,778 |
| Avg. Volume (3M) | 975,350 |
| Market Cap | 3,923,845,888 |
| Price / Earnings (Forward) | 17.83 |
| Price / Sales | 4.72 |
| 52 Weeks Range | |
| Earnings Date | 6 May 2025 |
| Profit Margin | -45.03% |
| Operating Margin (TTM) | -7.45% |
| Diluted EPS (TTM) | -4.73 |
| Quarterly Revenue Growth (YOY) | -30.60% |
| Current Ratio (MRQ) | 2.35 |
| Operating Cash Flow (TTM) | -107.69 M |
| Levered Free Cash Flow (TTM) | -80.23 M |
| Return on Assets (TTM) | -5.09% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | PTC Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | -3.0 |
| Price Volatility | -1.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -2.0 |
| Average | -1.50 |
|
PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when an RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 2.44% |
| % Held by Institutions | 99.81% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Rtw Investments, Lp | 31 Dec 2024 | 7,393,127 |
| Armistice Capital, Llc | 31 Dec 2024 | 6,378,000 |
| Toronto Dominion Bank | 31 Dec 2024 | 3,286,729 |
| Camber Capital Management Lp | 31 Dec 2024 | 3,200,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 113.00 (Cantor Fitzgerald, 128.19%) | Buy |
| Median | 65.00 (31.26%) | |
| Low | 45.00 (Citigroup, -9.13%) | Sell |
| Average | 68.29 (37.90%) | |
| Total | 4 Buy, 2 Hold, 1 Sell | |
| Avg. Price @ Call | 50.84 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| RBC Capital | 22 Apr 2025 | 65.00 (31.26%) | Buy | 48.19 |
| 18 Feb 2025 | 63.00 (27.22%) | Buy | 49.44 | |
| JP Morgan | 31 Mar 2025 | 75.00 (51.45%) | Buy | 50.96 |
| 14 Mar 2025 | 78.00 (57.51%) | Buy | 54.50 | |
| B of A Securities | 11 Mar 2025 | 55.00 (11.07%) | Hold | 52.59 |
| Morgan Stanley | 07 Mar 2025 | 70.00 (41.36%) | Buy | 52.59 |
| Scotiabank | 07 Mar 2025 | 55.00 (11.07%) | Hold | 52.59 |
| Citigroup | 12 Feb 2025 | 45.00 (-9.13%) | Sell | 48.93 |
| Cantor Fitzgerald | 03 Feb 2025 | 113.00 (128.19%) | Buy | 50.01 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| KLEIN MATTHEW B. | - | 48.19 | -2,804 | -135,125 |
| Aggregate Net Quantity | -2,804 | |||
| Aggregate Net Value ($) | -135,125 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 48.19 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| KLEIN MATTHEW B. | Officer | 22 Apr 2025 | Sell (-) | 2,804 | 48.19 | 135,125 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |